Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT

NCT ID: NCT04150965

Last Updated: 2025-02-14

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 14 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-07-10
• Study Completion Date: 2024-08-30

Brief Summary

This a Phase I/II randomized trial for patients with relapsed refractory Multiple Myeloma who have relapsed after treatment with prior therapies. The protocol is designed to evaluate two agents, Anti-LAG-3 and Anti-TIGIT, in order to understand their immunologic effects and safety both as single agents and in combination with pomalidomide and dexamethasone. In these arms, patients will be treated with either Anti-LAG-3 or Anti-TIGIT respectively for one cycle as single agent followed by the addition of pomalidomide and dexamethasone in combination for subsequent cycles.

A third arm allows patients to be treated with the FDA approved combination of elotuzumab plus pomalidomide and dexamethsone as a control. This arm will thus allow a concurrent standard of care comparator for the experimental arms.

Detailed Description

This study will enroll 104 patients to one of three treatment arms. The study is open to patients relapsing with refractory Multiple Myeloma who have:

• received 3 prior lines of therapy
• exposed to each of these 3 drug classes:

• IMiD
• proteasome inhibitors, and
• anti-CD38 monoclonal antibody
• relapsed and refractory are defined using the IMWG criteria:

• disease that is non-responsive while on salvage therapy or progresses within 60 days of last therapy in patients who have achieved minimal response or better at some point previously to then progressing in their disease course.

Conditions

Multiple Myeloma; Relapsed Refractory Multiple Myeloma

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Arm A - Elotuzumab

Patients receive Elotuzumab in combination with pomalidomide and dexamethasone. Arm A begings in Phase 2 portion.

Group Type: ACTIVE_COMPARATOR

Elotuzumab, pomalidomide, dexamethasone

Intervention Type: DRUG

Study Patients with relapsed Multiple Myeloma will receive: Elotuzumab, Pomalidomide, and Dexamethasone Starting in Phase 2 Cycle 1 Day 1 forward. Each cycle is 28 days long.

Arm B - Anti LAG-3 Single Agent

Patients receive Anti-LAG-3 as a single agent for 1 Cycle in Phase 1 portion.

Group Type: EXPERIMENTAL

Anti-LAG-3

Intervention Type: DRUG

Patients with relapsed Multiple Myeloma will receive: Anti -LAG-3 single agent for Cycle 1. Each Cycle is 28 days

Cycle 2 forward patients will receive Anti-LAG-3 in combination with pomalidomide and dexamethasone from Cycle 2 forward. Each cycle is 28 days long.

Arm B:Combination Anti LAG-3 +Pomalidomide+Dexamethasone

Cycle 2 and beyond Patients receive Anti-LAG-3 in combination with pomalidomide and dexamethasone.

Group Type: EXPERIMENTAL

Anti-LAG-3 + Pomalidimide + Dexamethasone

Intervention Type: DRUG

Patients with Relapsed \& Refractory Multiple Myeloma will receive: Anti-LAG-3 in combination with pomalidomide and dexamethasone from Cycle 2 forward. Each cycle is 28 days.

Arm C - Anti-TIGIT Single Agent

Patients receive Anti-TIGIT as a single agent for 1 Cycle in Phase 1 portion.

Group Type: EXPERIMENTAL

Anti-TIGIT

Intervention Type: DRUG

Patients with relapsed Multiple Myeloma will receive: Anti -TIGIT single agent for Cycle 1.

Each cycle is 28 days.

ARM C: Anti-TIGIT +Pomalidomide+Dexamethasone

Cycle 2 and beyond Patients receive Anti-TIGIT in combination with pomalidomide and dexamethasone.

Group Type: EXPERIMENTAL

Anti-TIGIT + Pomalidimide + Dexamethasone

Intervention Type: DRUG

Cycle 2 and beyond patients will receive Anti-TIGIT in combination with pomalidomide and dexamethasone from Cycle 2 forward. Each cycle is 28 days..

Interventions

Elotuzumab, pomalidomide, dexamethasone

Study Patients with relapsed Multiple Myeloma will receive: Elotuzumab, Pomalidomide, and Dexamethasone Starting in Phase 2 Cycle 1 Day 1 forward. Each cycle is 28 days long.

Intervention Type: DRUG

Anti-LAG-3

Patients with relapsed Multiple Myeloma will receive: Anti -LAG-3 single agent for Cycle 1. Each Cycle is 28 days

Cycle 2 forward patients will receive Anti-LAG-3 in combination with pomalidomide and dexamethasone from Cycle 2 forward. Each cycle is 28 days long.

Intervention Type: DRUG

Anti-LAG-3 + Pomalidimide + Dexamethasone

Patients with Relapsed \& Refractory Multiple Myeloma will receive: Anti-LAG-3 in combination with pomalidomide and dexamethasone from Cycle 2 forward. Each cycle is 28 days.

Intervention Type: DRUG

Anti-TIGIT

Patients with relapsed Multiple Myeloma will receive: Anti -TIGIT single agent for Cycle 1.

Each cycle is 28 days.

Intervention Type: DRUG

Anti-TIGIT + Pomalidimide + Dexamethasone

Cycle 2 and beyond patients will receive Anti-TIGIT in combination with pomalidomide and dexamethasone from Cycle 2 forward. Each cycle is 28 days..

Intervention Type: DRUG

Other Intervention Names

Empliciti; BMS-986016; Anti LAG-3; Relatlimab; BMS-986016; Anti-LAG-3, Pomalidomide, Dexamethasone; BMS-986207; BMS-986207

Eligibility Criteria

Inclusion Criteria

1. 18 years of age or greater.

2. Willing and able to provide informed consent

3. Patient has received at least 3 prior lines of therapy and must have received prior therapy including at least one drug from each drug class; IMiD, proteasome inhibitors, and anti-CD38 monoclonal antibody.

4. The following laboratory values obtained ≤ 14 days prior to initiation of therapy:

1. ANC ≥ 1000/ul (without growth factor support within 14 days of initiation of therapy)

2. Hgb ≥ 8 g/dl

3. PLT ≥ 75,000/ul (without transfusion support within 14 days of initiation of therapy)

4. Total bilirubin <1.5 x upper limit of normal (ULN) or if total bilirubin is ≥1.5 x ULN, the direct bilirubin must be ≤ 2.0 mg/dL (patients with Gilberts syndrome may have total bilirubin ≤3.0 x ULN

5. AST and ALT < 2.5x ULN

6. Creatinine Clearance ≥ 30 mL/min by Cockcroft Gault Equation

5. Measurable disease of MM as defined by at least ONE of the following:

1. Serum monoclonal protein ≥1.0 g by protein electrophoresis

2. ≥200 mg of monoclonal protein in the urine on 24-hour electrophoresis

3. Serum immunoglobulin FLC ≥10 mg/dL AND abnormal serum immunoglobulin kappa to lambda FLC ratio.

6. Normal thyroid function, or stable on hormone supplementation per investigator assessment.

7. Eastern Cooperative Oncology Group (ECOG) Performance Status 0, 1, or 2.

8. Willingness to return to enrolling institution for follow-up.

9. Disease free of prior malignancies for ≥ 3 year with exception of currently treated basal cell, squamous cell carcinoma of the skin, carcinoma "insitu" of the cervix or breast, or prostate cancer not requiring therapy

10. Ability to understand the purpose and risks of the study and provide signed and dated ICF and authorization to use protected health information.

11. All study participants must be willing to be registered into, and comply with, the mandatory pomalidomide (POMALYST®) Risk Evaluation and Mitigation Strategy (REMS®) program and be willing to use contraception 28 days prior to pomalidomide treatment and continue until 120 days after the last dose of pomalidomide.

12. Able to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation. For patient's intolerant to aspirin or for high-risk patients with prior history of thromboembolic events, thromboprophylaxis with other anti-coagulants agents, including low molecular weight heparin, warfarin, or novel oral anticoagulants such as apixaban or rivaroxaban, is allowed.

13. All females of child bearing potential (FCBP)* must have a negative pregnancy test (urine or serum) documented ≤7 days prior to start of therapy with repeat pregnancy test on Day 1 of each cycle and at the EoT visit. Note: Additional pregnancy testing is required as a condition of the POMALYST REMS® program prior to and while on treatment and following the last dose of pomalidomide. FCBP must have 2 negative pregnancy tests prior to initiating pomalidomide treatment. The first test should be performed within 10-14 days prior to prescribing POMALYST and the second test within 24 hours prior to prescribing POMALYST therapy and then weekly during the first 4 weeks, then every 4 weeks thereafter in females with regular menstrual cycles, or every 2 weeks in females with irregular menstrual cycles. Protocol section 8.1 provides guidelines on the use and required time frames of contraception. NOTE: *A female of childbearing potential (FCBP) is a sexually mature female who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).

Exclusion Criteria

1. Patient is known to be human immunodeficiency virus (HIV) positive, Hepatitis B surface antigen-positive, Hep B PCR positive or active Hepatitis C infection

2. Pregnant or breast feeding females;

3. Any clinically significant, uncontrolled medical conditions including, but not limited to, myocardial infarction or stroke/transient ischemic attack within the past 6 months, uncontrolled angina within the past 3 months, symptomatic congestive heart failure, cardiac arrhythmia (such as ventricular tachycardia, ventricular fibrillation, or torsades de pointes), pericarditis, myocarditis, cardiomyopathy, requirement for supplemental oxygen;

4. Any psychiatric illness/social situations that, in the Investigator's opinion, would impose excessive risk to the patient or may interfere with compliance or interpretation of the study results;

5. QT interval corrected for heart rate using Fridericia's formula (QTcF) prolongation > 480 msec, except for right bundle branch block;

6. Ongoing or active infection, that requires systemic antibacterial, antiviral, or antifungal therapy < 7 days prior to the initiation of therapy

7. Inability to tolerate thromboprophylaxis ;

8. Known CNS involvement;

9. Known severe intolerance to steroid therapy (Grade 3 or above adverse event unresponsive to dose reduction and/or per investigators discretion);

10. History of autoimmune disease, requiring therapy including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Bell's palsy, Guillain-Barré syndrome, multiple sclerosis, vasculitis, glomerulonephritis, or suspected autoimmune disease. (Subjects are permitted to enroll if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, euthyroid with a history of Grave's disease (participants with suspected autoimmune thyroid disorders must be negative for thyroglobulin and thyroid peroxidase antibodies and thyroid stimulating Ig prior to the first dose of study drug), psoriasis not requiring systemic treatment, well controlled asthma and/or mild allergic rhinitis [seasonal allergies], or conditions not expected to recur in the absence of an external trigger);

11. NYHA Classification > Class 2;

12. Concurrent amyloidosis, plasma cell leukemia or POEMS syndrome [plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein (M-protein) and skin changes;

13. History of erythema multiforme or severe (≥ grade 3) hypersensitivity to prior IMiD's;

14. 14. Anti-cancer therapy within the specified time frames prior to initiation of therapy: cytotoxic investigational agents, within 3 weeks (6 weeks for nitrosoureas), IMiDs, Proteosome inhibitors or corticosteroids within 2 weeks, investigational therapies within 14 days or 5 half-lives of the investigational drug, whichever is longer, and monoclonal antibodies within 4 weeks, bispecifics (antibodies) within 4 weeks, CAR-T within 4 weeks post infusion. Prednisone up to but no more than 10 mg orally q.d. or its equivalent for symptom management of comorbid conditions is permitted but dose should be stable for at least 7 days. Live vaccines within 30 days (The inactivated seasonal influenza vaccine can be given to patients before treatment and while on therapy without restriction). Shorter time lines may be considered in consultation with the PI;

15. Prior major surgery or radiation therapy within 4 weeks of initiation of therapy;

16. Prior therapy with Anti-TIGIT or Anti-LAG-3 ; Elotuzumab

17. Any > Grade 1 adverse reaction unresolved from previous treatments according to the NCI CTC AE v 5.0. The presence of alopecia or peripheral neuropathy ≤ Grade 2 without pain is allowed;

18. Previous allogeneic stem cell transplantation;

19. Immunosuppressive therapy in the last 2 months prior to initiation of therapy;

20. Autologous stem cell transplant if < 12 weeks from initiation of therapy;

21. History of idiopathic pulmonary fibrosis, organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.);

22. Cardiac Troponin T (cTnT) or I(cTnI)≥2×institutional ULN.

1. Subjects with cTnT or cTnI levels between > 1 to 2 × ULN will be permitted if repeat levels within 24 hours are ≤ 1 ULN

2. If cTnT or cTnI levels are >1 ULN at 24 hours, the subject may undergo a cardiac evaluation and be considered for treatment, following a discussion with the Principal Investigator.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Bristol-Myers Squibb

INDUSTRY

Sponsor Role: collaborator

Emory University

OTHER

Sponsor Role: collaborator

Washington University School of Medicine

OTHER

Sponsor Role: collaborator

Beth Israel Deaconess Medical Center

OTHER

Sponsor Role: collaborator

Dana-Farber Cancer Institute

OTHER

Sponsor Role: collaborator

Wake Forest University Health Sciences

OTHER

Sponsor Role: collaborator

Memorial Sloan Kettering Cancer Center

OTHER

Sponsor Role: collaborator

Icahn School of Medicine at Mount Sinai

OTHER

Sponsor Role: collaborator

University of Texas

OTHER

Sponsor Role: collaborator

Hackensack Meridian Health

OTHER

Sponsor Role: collaborator

University of Michigan

OTHER

Sponsor Role: collaborator

Multiple Myeloma Research Consortium

NETWORK

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Madhav V. Dhodapkar, M.D.

Role: PRINCIPAL_INVESTIGATOR

Medical Monitor

Hearn J. Cho, M.D., Ph.D.

Role: PRINCIPAL_INVESTIGATOR

Chief Medical Officer

Locations

Emory University

Atlanta, Georgia, United States

Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States

Dana Farber Cancer Institute

Boston, Massachusetts, United States

University of Michigan

Ann Arbor, Michigan, United States

Washington University School of Medicine Division of Medical Oncology

St Louis, Missouri, United States

Hackensack Meridian Medical Center

Hackensack, New Jersey, United States

Mount Sinai School of Medicine

New York, New York, United States

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Levine Cancer Institute

Charlotte, North Carolina, United States

UT Southwestern Medical Center

Dallas, Texas, United States

Countries

United States

References

Richard S, Lesokhin AM, Paul B, Kaufman JL, Pianko M, Biran N, Vij R, Doxie DB, Azeem MI, Martillo M, Wozniak K, Cho HJ, Dhodapkar KM, Dhodapkar MV. Clinical response and pathway-specific correlates following TIGIT-LAG3 blockade in myeloma: the MyCheckpoint randomized clinical trial. Nat Cancer. 2024 Oct;5(10):1459-1464. doi: 10.1038/s43018-024-00818-w. Epub 2024 Aug 26.

Reference Type: DERIVED

PMID: 39187595 (View on PubMed)

Other Identifiers

MyCheckpoint (MMRC-089)

Identifier Type: -

Identifier Source: org_study_id